Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Cardiol Therapeutics Inc
CRDL
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.12
N/A
Ult. Agg.: Oct 26, 4:05 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Confronta
Opzioni
Rapporto azionario
Cardiol Therapeutics Financials
Cardiol Therapeutics (CRDL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Cardiol Therapeutics Q3 EPS $(0.09), Inline
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 30.77 percent increase over losses of $(0.13) per share from the same period last
Benzinga Newsdesk
AZZ, Helen of Troy And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
PRO
Cardiol Therapeutics Q4 EPS $(0.09) Beats $(0.12) Estimate
Cardiol Therapeutics (NASDAQ:CRDL) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 12.5 percent decrease over losses of $(0.08) per share from
Benzinga Newsdesk
PRO
Cardiol Therapeutics' Cash And Cash Equivalents Of $34.9M As Of December 31, 2023, Which Funds Operations Into 2026
Benzinga Newsdesk
Mid-Morning Market Update: Markets Mostly Lower; CVS Health Tops Q3 Views
Following the market opening Wednesday, the Dow traded down 0.31% to 35,939.39 while the NASDAQ fell 0.01% to 15,649.42. The S&P also fell, dropping 0.15% to 4,623.92.
Lisa Levin
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8)
Shanthi Rexaline
